SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy
Study Evaluating Everolimus with Endocrine Therapy in Breast Cancer Patients
Sponsor: Southwest Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAL3751
U.S. Govt. ID: NCT01674140
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without the subjects cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer. It is considered investigational for breast cancer patients. In this study the subject will get hormone treatment with either everolimus or with placebo (a pill with no medication). The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.
This study is closed
Dawn Hershman, MD
Do You Qualify?
Do you have breast cancer? Yes No
Have you completed any chemotherapy or radiation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator